The Emergence of Nanopharmacy: From Biology to Nanotechnology and Drug Molecules to Nanodrugs

Hadjidemetriou, Marilena; Al-Ahmady, Zahraa S.; Mazza, Mariarosa; Kostarelos, Kostas

doi:10.1002/9783527800681.ch3

Cited by 2 publications

(2 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Deciphering the recognition between corona proteins and cell receptors 63,64,67 could help us toward understanding exactly how BC-decorated lipid vesicles interact with cells and biological barriers, potentially activating different biological pathways. To this end, reproducible methods must be clearly established that comprise the recovery of liposomes after dynamic incubation 68 and/or systemic administration in vivo, 46,69,70 thorough characterization of the BC, and evaluation of corresponding biological interactions. We foresee that these future advances will yield new opportunities for accelerating the clinical translation of liposomal drugs for brain delivery.…”

Section: ■ Conclusionmentioning

confidence: 99%

Brain Targeting by Liposome–Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells

Arcella

Palchetti

Digiacomo

et al. 2018

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Temozolomide (TMZ) is the current first-line chemotherapy for treatment of glioblastoma multiforme (GBM). However, similar to other brain therapeutic compounds, access of TMZ to brain tumors is impaired by the blood-brain barrier (BBB) leading to poor response for GBM patients. To overcome this major hurdle, we have synthesized a set of TMZ-encapsulating nanomedicines made of four cationic liposome (CL) formulations with systematic changes in lipid composition and physical-chemical properties. The targeting nature of this nanomedicine is provided by the recruitment of proteins, with natural targeting capacity, in the biomolecular corona (BC) layer that forms around CLs after exposure to human plasma (HP). TMZ-loaded CL-BC complexes were thoroughly characterized by dynamic light scattering (DLS), electrophoretic light scattering (ELS), and nanoliquid chromatography tandem mass spectrometry (nano-LC MS/MS). BCs were found to be enriched of typical BC fingerprints (BCFs) (e.g., Apolipoproteins, Vitronectin, and vitamin K-dependent protein), which have a substantial capacity in binding to receptors that are overexpressed at the BBB (e.g., scavenger receptor class B, type I and low-density lipoprotein receptor). We found that the CL formulation exhibiting the highest levels of targeting BCFs had larger uptake in human umbilical vein endothelial cells (HUVECs) that are commonly used as an in vitro model of the BBB. This formulation could also deliver TMZ to the human glioblastoma U-87 MG cell line and thus substantially enhance their antitumor efficacy compared to corona free CLs. Thus, we propose that the BC-based nanomedicines may pave a more effective way for efficient treatment of GBM.

show abstract

Section: ■ Conclusionmentioning

confidence: 99%

Brain Targeting by Liposome–Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells

Arcella

Palchetti

Digiacomo

et al. 2018

ACS Chem. Neurosci.

View full text Add to dashboard Cite

show abstract

“…-«Фармацевтичні нанотехнології» (pharmaceutical nanotechnology) або «нанофармація» (nanopharmaceuticals, nanopharmacy) − розробка нових ліків, а також фармацевтичних, терапевтичних і діагностичних засобів та методів їх націлювання, раціональної доставки та контролю вивільнення. Отже, основною метою нанофармації є використання нанонауки для створення нових препаратів з підвищеною терапевтичною ефективністю [5].…”

unclassified

Огляд Сучасних Підходів До Розробки Наноліків

Брубейкер¹,

Білан²,

Marchenko-Tolsta³

2020

RS Global - World Science

View full text Add to dashboard Cite

The article deals with nanopharmacy, a new medical discipline that combines chemistry, physics and engineering to develop nanoscale systems used in diagnosis and therapy. The use of nanoparticles for the development of new nanodrugs requires a deep understanding not only of the properties of nanomaterials, but also of the pathophysiology of diseases. Nanopharmacy help solve complex problems associated with improving the effectiveness of existing therapeutic agents and the use of nanomaterials in the manufacture of nanodrugs.

show abstract

The Emergence of Nanopharmacy: From Biology to Nanotechnology and Drug Molecules to Nanodrugs

Cited by 2 publications

References 80 publications

Brain Targeting by Liposome–Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells

Brain Targeting by Liposome–Biomolecular Corona Boosts Anticancer Efficacy of Temozolomide in Glioblastoma Cells

Огляд Сучасних Підходів До Розробки Наноліків

Contact Info

Product

Resources

About